Liu Zhuang, Hu Wei, Sun Jiali, Wang Liang, Song Dan, Guo Lei
Children's Hospital Affiliated to Shandong University, Jinan, China.
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Jinan, China.
Front Pediatr. 2022 Jul 28;10:925318. doi: 10.3389/fped.2022.925318. eCollection 2022.
The aim of this study was to investigate the efficacy of polidocanol against venous malformations (VMs).
Studies reporting the treatment of VMs using polidocanol (published until February 15, 2020) were reviewed in the Embase and PubMed databases. After excluding the same literature, part of the studies were excluded by reading the title, abstract, full text. Eleven studies (with 287 participants) that fulfilled the inclusion criteria were included. Systematic meta-analysis was performed using Reviews Manager 5.2, and a fixed-effects model was used to calculate the pooled effective rate of polidocanol against VMs and the 95% confidence intervals (CI).
Lesion reduction of more than 50% was considered effective. A total of 287 patients were treated, and treatment in 271 was considered effective. The efficacy of polidocanol was 0.89 (95% CI = 0.83-0.93). Heterogeneity among the studies was small ( = 0%, = 0.47). T The funnel plot was roughly symmetric.
Our study suggested that polidocanol is effective in the treatment of VMs. VMs at different sites can be treated without serious complications. Therefore, we have reason to believe that polidocanol is a safe and an effective drug for VMs.
本研究旨在探讨聚多卡醇治疗静脉畸形(VMs)的疗效。
在Embase和PubMed数据库中检索截至2020年2月15日发表的关于使用聚多卡醇治疗VMs的研究。排除重复文献后,通过阅读标题、摘要和全文排除部分研究。纳入11项符合纳入标准的研究(共287名参与者)。使用RevMan 5.2进行系统荟萃分析,采用固定效应模型计算聚多卡醇治疗VMs的合并有效率及95%置信区间(CI)。
病变缩小超过50%被认为有效。共治疗287例患者,其中271例治疗有效。聚多卡醇的疗效为0.89(95%CI = 0.83 - 0.93)。研究间异质性较小(I² = 0%,P = 0.47)。漏斗图大致对称。
我们的研究表明聚多卡醇治疗VMs有效。不同部位的VMs均可治疗且无严重并发症。因此,我们有理由相信聚多卡醇是一种治疗VMs安全有效的药物。